Our study also suggests that RRM2B-specific inhibitors, if can be developed, will be promising anti-cancer agents to be combined with standard treatment for its critical role in drug resistance and relapse of cancer cells but the non-essential role in normal cells. This evidence concerns the gene RRM2B and cancer.